Barclays PLC Buys 40,319 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Barclays PLC increased its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 91.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,572 shares of the company’s stock after acquiring an additional 40,319 shares during the quarter. Barclays PLC owned approximately 0.12% of Amylyx Pharmaceuticals worth $274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of AMLX. China Universal Asset Management Co. Ltd. grew its holdings in shares of Amylyx Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock worth $42,000 after purchasing an additional 5,104 shares during the last quarter. Algert Global LLC purchased a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $47,000. Hsbc Holdings PLC grew its holdings in Amylyx Pharmaceuticals by 57.9% in the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after acquiring an additional 27,954 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at about $156,000. Finally, Maven Securities LTD increased its position in shares of Amylyx Pharmaceuticals by 300.0% in the second quarter. Maven Securities LTD now owns 100,000 shares of the company’s stock valued at $190,000 after acquiring an additional 75,000 shares during the period. 95.84% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amylyx Pharmaceuticals

In other news, CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the transaction, the chief executive officer now directly owns 3,176,788 shares in the company, valued at approximately $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Stock Up 2.9 %

NASDAQ AMLX opened at $3.60 on Tuesday. The firm has a market capitalization of $246.78 million, a PE ratio of -0.94 and a beta of -0.53. The stock’s 50 day moving average is $4.54 and its 200 day moving average is $3.53. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.95.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on AMLX shares. Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Leerink Partners set a $4.00 target price on Amylyx Pharmaceuticals and gave the company a “market perform” rating in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Finally, Bank of America raised shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $4.20 to $10.00 in a research report on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.